The effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol were investigated. Pyrazinamide decreased the mean (SEM) fractional clearance of oxypurinol from 19-2 (2-1) to 8-8 (1-5). Probenecid increased the fractional clearance of oxypurinol from 14*1 (3.5) to 24-8 (4-1). Benzbromarone increased the fractional clearance of oxypurnol from 15-6 (2.3) to 33-8 (2.8). These results suggest that oxypurinol may be secreted by 'an organic acid system' and that oxypurinol is reabsorbed at a putative postsecretory site of the renal tubules.
Oxypurinol is a major metabolite of allopurinol, which is now widely used for the control of uric acid production in patients with gout. Oxypurinol is a strong inhibitor of xanthine oxidase, its inhibitory potency being similar to that of allopurinol, and it has a longer half life (13) (14) (15) (16) (17) (18) hours) than allopurinol (0-6-1-6 hour). l-5 Therefore, the effect of allopurinol on uric acid production can be attributed almost entirely to oxypurinol. In normal subjects and patients with gout allopurinol is mainly converted to oxypurinol by xanthine oxidase, and oxypurinol is then excreted unchanged by the kidney. 2 The concentration of serum oxypurinol is directly related to the renal clearance of oxypurinol,4 which increases or decreases under various conditions.4 6 For treatment of patients with gout, therefore, it is important to understand the renal excretion of oxypurinol. The renal excretion of oxypurinol seems to be similar to that of uric acid,4 7 but the renal transport mechanism(s) of oxypurinol has not yet been clearly elucidated. Probenecid and benzbromarone are two uricosuric agents, which seem mainly to inhibit the renal reabsorption of uric acid at the postsecretory site8'0 (fig 1) . Pyrazinamide is an antituberculous agent and is well known to inhibit the renal secretion of uric acid8 (fig 1) . These three agents have therefore been used to study the renal transport of uric acid." 12 As the renal excretion of oxypurinol is similar to tht of uric acid,4 in this study we investigated the renal excretion of oxypurinol using these drugs (pyrazinamide, probenecid, and benzbromarone).
Materials and methods

CHEMICALS
Oxypurinol and allopurinol were kindly provided by Tanabe (Osaka, Japan 17 except in the study by Cohn et al,7 which showed that oral administration of 100 mg/day or 20 mg/day of benzbromarone for seven days increased F.. in normal subjects.
Colin et al suggested that the absence of an observed pharmacokinetic interaction between benzbromarone and oxypurinol in previous studies was due to the slow onset of action of benzbromarone because all previous studies had been conducted using a single high dose schedule (allopurinol 300 mg, benzbromarone 60 mg).'6 '7 Their speculation led us to suspect that even a single dose of benzbromarone might increase Fox if it exerted a sufficiently strong uricosuric action. Therefore, we tested the effect of a single very high dose schedule (allopurinol 300 mg, benzbromarone 300 mg) and found that benzbromarone did in fact increase F.. (fig 4) , indicating that the hypouricaemic effect of combination therapy with allopurinol and benzbromarone on plasma uric acid may be less than additive, as reported by Von Loffler et al'8 and that oxypurinol may be reabsorbed at least at a postsecretory site of the tubules ( fig 5) .
